A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety and Tolerability of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects With Pulmonary Arterial Hypertension or Pulmonary Hypertension Associated With Interstitial Lung Disease
Latest Information Update: 14 Oct 2024
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Registrational
- Sponsors Liquidia Technologies
Most Recent Events
- 09 Oct 2024 Status changed from recruiting to active, no longer recruiting.
- 22 May 2024 Results (n=15) presented at the 120th International Conference of the American Thoracic Society
- 10 May 2024 According to a Liquidia Technologies media release, data from this study will be presented at the American Thoracic Society (ATS) 2024 International Conference